Show simple item record

dc.contributor.authorDreyling, M
dc.contributor.authorMorschhauser, F
dc.contributor.authorBouabdallah, K
dc.contributor.authorCunningham, D
dc.contributor.authorBron, D
dc.contributor.authorLinton, Kim M
dc.contributor.authorAssouline, S
dc.contributor.authorVerhoef, G
dc.contributor.authorThieblemont, C
dc.contributor.authorVitolo, U
dc.contributor.authorGarcia-Vargas, J
dc.contributor.authorGorbatchevsky, I
dc.contributor.authorNeves, M
dc.contributor.authorGrunert, J
dc.contributor.authorHiemeyer, F
dc.contributor.authorChilds, B
dc.contributor.authorZinzani, P
dc.date.accessioned2016-12-16T16:21:25Z
dc.date.available2016-12-16T16:21:25Z
dc.date.issued2016
dc.identifier.citationPhase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. 2016, 39: 310-310 Oncol Res Treaten
dc.identifier.urihttp://hdl.handle.net/10541/620062
dc.language.isoenen
dc.titlePhase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversitatsklinik Grosshadern/LMU, Medizinische Klinik 111, Munchenen
dc.identifier.journalOncology Research and Treatmenten
dc.description.collectionLymphoma Research Teamen


This item appears in the following Collection(s)

Show simple item record